1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

31 May 2023
Admin
News Article

Galvanize Announces License Agreement And Partnership With Energenx Medical For Its Technologies In China

License Will Maximize The Availability Of Pulsed Electric Field Therapies For The PopulationEnergenx Has Obtained Green Channel Approval For Rheox, Galvanize'S Proprietary Pulsed Electric Field (Pef) System For The Treatment Of Chronic BronchitisThe First Patient Was Enrolled In The China Rheox Clinical Trial For Chronic Bronchitis Galvanize Therapeutics, Inc., A Leader In Developing Pulsed Electric Field Therapies For Copd, Solid Tumors And Cardiac Arrhythmias, Announced Today That The Company Has Signed An Exclusive License Agreement With Energenx Medical, Ltd To Develop And Commercialize Its Products In Mainland China, Hong Kong, Taiwan, And Macau. Recognizing The Potential For Its Technologies In China, Galvanize Worked With Its Founding Investor Apple Tree Partners (Atp) To Form Energenx In 2021. Headquartered In Shanghai, The Company Is Led By Founder & Ceo Zhengrong Zhou, Ph.D., A Veteran Of The Medical Device Industry In The United States And China Who Most Recently Spent A Decade In Leadership Positions At Medtronic China. Energenx Will Further Develop And Manufacture Galvanize'S Rheox And Aliya Systems In China, According To The Needs Of Local Physicians And Patients, And Will Conduct Clinical Trials To Seek Local Regulatory Approval. In January 2023, Energenx Received Approval From The Medical Device Technical Evaluation Center (Cmde) Of The China National Medical Products Administration (Nmpa) For Rheox To Enter The "Green Channel Special Review Process," Under Which Regulatory Review Times May Be Accelerated. Jonathan Waldstreicher, Md, Founder & Ceo Of Galvanize, Commented: "We Are Thrilled To Partner With Energenx To Bring Access To The Rheox Therapy To More Patients To Treat The Symptoms Of Chronic Bronchitis. Zhengrong Has Built A World Class Team That Has Worked Hand-In-Hand With Our Galvanize Employees To Launch This Treatment, Which We Believe Promises To Greatly Improve Health And Quality Of Life For Those People Living With Chronic Bronchitis. We Are Also Excited To Advance Our Aliya Soft Tissue Ablation System In China Through Our Relationship With Energenx."Dr. Zhengrong Zhou Said: "We Are Very Excited To Work With Galvanize To Promote The Development Of Innovative Therapies For Lung Disease And Oncology With Top Experts At Home And Abroad. Using Rheox As The First Collaboration Opportunity, Together, We Are Establishing Leadership In Interventional Pulmonology With Continued Pipelines In China And Globally. Rheox Is Expected To Become The First Commercially Available Pulsed Electric Field Respiratory Intervention Technology To Treat The Symptoms Of Chronic Bronchitis In China, Benefiting A Broad Base Of Copd Patients."On May 18, 2023, Professor Guangfa Wang, Director Of The Department Of Respiratory And Critical Care Medicine At Peking University 1St Hospital In Beijing, Treated The First Copd Patient As Part Of The Rheox China Study For Patients With Chronic Bronchitis. The Procedure Was Performed Using A Minimally-Invasive Approach Through A Bronchoscope And The Patient Was Discharged Soon After Without Complications.About Rheox

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!